Is upadacitinib (Rinvoq) effective for both ulcerative colitis (UC) and Crohn's disease (CD) in an adult with moderate-to-severe UC who previously failed adalimumab and responded to tofacitinib?

Upadacitinib Efficacy in Ulcerative Colitis and Crohn's Disease

Yes, upadacitinib is FDA-approved and highly effective for both moderate-to-severe ulcerative colitis (UC) and Crohn's disease (CD) in adults who have failed or are intolerant to one or more TNF blockers. 1

Regulatory Status and Indications

• Ulcerative Colitis: Upadacitinib received FDA approval for moderate-to-severe UC in adults with inadequate response or intolerance to ≥1 TNF blocker. 1

• Crohn's Disease: Upadacitinib is FDA-approved for moderate-to-severe CD in adults with inadequate response or intolerance to ≥1 TNF blocker. 1

• Both indications explicitly permit use after prior TNF antagonist failure, making upadacitinib an appropriate option for your patient who previously failed adalimumab. 1

Clinical Efficacy Data

Ulcerative Colitis Performance

• Network meta-analysis evidence: In TNF-exposed UC patients, upadacitinib outperforms tofacitinib, ustekinumab, vedolizumab, adalimumab, and ozanimod—establishing it as the preferred agent in this population. 2

• Clinical remission rates: Pooled data show 25.4% remission in registration trials (95% CI 0.17-0.36), with clinical response rates of 72.6% (95% CI 0.69-0.76). 3

• Real-world outcomes: In a large prospective cohort, 81.5% achieved clinical remission by week 8, with response rates of 85.2%. 4 Another multicenter Australian cohort demonstrated 84% clinical remission at week 16. 5

• Rapid onset: Approximately 36% of UC patients achieve clinical remission as early as week 2, providing swift symptom relief. 2, 4

Crohn's Disease Performance

• Comparative effectiveness: In TNF-exposed CD patients, upadacitinib is preferred alongside risankizumab, both superior to ustekinumab, adalimumab, and vedolizumab, with no clear superiority between the two. 2

• Clinical remission rates: Pooled analysis shows 45.8% remission (95% CI 0.39-0.52) and 53.6% clinical response (95% CI 0.50-0.57). 3

• Real-world data: In prospective cohorts, 70.6% achieved clinical remission by week 8, with 76.5% response rates. 4 A separate multicenter study reported 30.3% remission with 69.7% response at last follow-up. 6

• Early response: 56.3% of CD patients achieved clinical remission by week 2. 4

Dosing Strategy

Standard Regimen

• Induction: 45 mg orally once daily for 8 weeks (UC) or 12 weeks (CD). 1

• Maintenance: Typically 15 mg or 30 mg once daily; however, a subset requires continuation of 45 mg daily to sustain response. 2, 1

Dose De-escalation Risks

• Critical consideration: Among patients who de-escalated from higher to lower JAK inhibitor doses, approximately 29% required dose re-escalation, and only 63% regained clinical response after re-escalation. 2

• Maintenance strategy: In patients who lose response after dose reduction to 30 mg, reinduction with 45 mg recaptures response in 80.4%. Among those recaptured, 93.8% maintained remission on continued 45 mg versus only 21.1% who again reduced to 30 mg (p < 0.001). 7

• For your patient: Given the history of tofacitinib response and adalimumab failure, consider maintaining 45 mg daily rather than de-escalating, particularly if adherence concerns exist or if the patient has a pattern of disease flare with dose reduction. 2, 7

Tofacitinib Cross-Over Efficacy

• Direct evidence: Among UC patients with prior tofacitinib exposure, 77.8% achieved clinical remission by week 8 with upadacitinib. 4

• Real-world confirmation: A multicenter Australian study found no significant difference in week 16 clinical remission between tofacitinib-experienced versus tofacitinib-naïve patients (86% vs. 84%, P=0.67). 5

• Mechanistic rationale: While both are JAK inhibitors, upadacitinib's greater JAK1 selectivity and higher potency may explain efficacy in tofacitinib-exposed patients. 8

Safety Profile

Common Adverse Events

• Most frequent: Acne/rosacea occurs in 22.9-39% of patients and is the most commonly reported adverse event. 4, 7

• Other common events: Nasopharyngitis, creatine phosphokinase elevation, headache, anemia, and upper respiratory tract infections. 9

• Serious adverse events: Overall rate of 6.0-7.8% across pooled studies. 3, 10

Adverse Events of Special Interest

• Herpes zoster: Dose-dependent risk; consider vaccination prior to initiation when not contraindicated. 8, 2

• Venous thromboembolism: Increased risk with higher doses, particularly relevant in patients with prior VTE history. 2, 1

• Lipid changes: Monitor cholesterol levels approximately 12 weeks after initiation. 8, 2

• Serious infections: Numerically higher rates observed in CD compared to placebo, though generally comparable across subgroups. 10

• GI perforation: Risk in patients with diverticulitis history or concurrent NSAID/corticosteroid use. 1

Monitoring Requirements

• Baseline labs: Complete blood count (neutrophils, lymphocytes, hemoglobin), liver enzymes, lipid panel. 8

• During treatment: Repeat labs if clinical concern arises; do not initiate if neutrophil count, lymphocyte count, or red blood cell count is too low, or if liver enzymes are significantly elevated. 1

Positioning in Your Patient

For an adult with moderate-to-severe UC who failed adalimumab and responded to tofacitinib, upadacitinib is the optimal next-line agent based on:

1. Superior efficacy: Network meta-analysis establishes upadacitinib as the preferred agent in TNF-exposed UC, outperforming all comparators including tofacitinib. 2

2. Proven tofacitinib cross-over success: High remission rates (77.8-86%) in tofacitinib-experienced patients. 4, 5

3. Rapid symptom control: Early remission by week 2 in over one-third of patients supports swift disease control. 2, 4

4. Once-daily dosing: May improve adherence compared to twice-daily tofacitinib. 2

Key Clinical Pitfalls

• Premature dose reduction: Avoid de-escalating from 45 mg to 30 mg or 15 mg in patients with prior non-compliance or disease flare history, as recapturing response is difficult (only 63% success rate). 2, 7

• Inadequate monitoring: Failure to check baseline and follow-up labs (CBC, liver enzymes, lipids) can miss treatable adverse events. 8, 1

• Ignoring VTE risk factors: Screen for prior thromboembolism history and avoid in high-risk patients or use with extreme caution. 2, 1

• Concurrent immunosuppression: Do not combine with other JAK inhibitors, biologics, or potent immunosuppressants (azathioprine, cyclosporine). 1